{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:34:01Z","timestamp":1791232441546,"version":"4.1.0"},"reference-count":118,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.iac.2014.01.009","type":"journal-article","created":{"date-parts":[[2014,4,17]],"date-time":"2014-04-17T17:48:43Z","timestamp":1397756923000},"page":"239-262","source":"Crossref","is-referenced-by-count":76,"title":["Molecular Defects in Mastocytosis"],"prefix":"10.1016","volume":"34","author":[{"given":"Siham","family":"Bibi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Langenfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvie","family":"Jeanningros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabienne","family":"Brenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erinn","family":"Soucie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Dubreuil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2014.01.009_bib1","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13)","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib2","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1182\/blood-2007-11-078097","article-title":"Mast cells and mastocytosis","volume":"112","author":"Metcalfe","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib3","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.4049\/jimmunol.156.12.4839","article-title":"Mast cells expressing chymase but not tryptase can be derived by culturing human progenitors in conditioned medium obtained from a human mastocytosis cell strain with c-kit ligand","volume":"156","author":"Li","year":"1996","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.iac.2014.01.009_bib4","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0167-5699(94)90153-8","article-title":"The riddle of the mast cell: kit(CD117)-ligand as the missing link?","volume":"15","author":"Valent","year":"1994","journal-title":"Immunol Today"},{"key":"10.1016\/j.iac.2014.01.009_bib5","first-page":"399","article-title":"Systemic mastocytosis","volume":"142","author":"Valent","year":"2008","journal-title":"Cancer Treat Res"},{"key":"10.1016\/j.iac.2014.01.009_bib6","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1586\/ehm.10.42","article-title":"Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives","volume":"3","author":"Arock","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.iac.2014.01.009_bib7","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1159\/000048179","article-title":"Kit and c-kit mutations in mastocytosis: a short overview with special reference to novel molecular and diagnostic concepts","volume":"127","author":"Feger","year":"2002","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.iac.2014.01.009_bib8","doi-asserted-by":"crossref","first-page":"e43090","DOI":"10.1371\/journal.pone.0043090","article-title":"Single nucleotide polymorphism array lesions, TET2, DNMT3A, ASXL1 and CBL mutations are present in systemic mastocytosis","volume":"7","author":"Traina","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.iac.2014.01.009_bib9","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib10","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib11","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1532\/IJH97.07053","article-title":"Development of mast cells: analysis with mutant mice","volume":"86","author":"Morii","year":"2007","journal-title":"Int J Hematol"},{"key":"10.1016\/j.iac.2014.01.009_bib12","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood.V87.8.3117.bloodjournal8783117","article-title":"A\u00a0point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells","volume":"87","author":"Piao","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib13","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1084\/jem.183.6.2681","article-title":"Recombinant human stem cell factor (kit ligand) promotes human mast cell and melanocyte hyperplasia and functional activation in\u00a0vivo","volume":"183","author":"Costa","year":"1996","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.iac.2014.01.009_bib14","first-page":"373","article-title":"Alternate splicing of mRNAs encoding human mast cell growth factor and localization of the gene to chromosome 12q22-q24","volume":"2","author":"Anderson","year":"1991","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.iac.2014.01.009_bib15","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/S1357-2725(99)00076-X","article-title":"The biology of stem cell factor and its receptor C-kit","volume":"31","author":"Ashman","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.iac.2014.01.009_bib16","first-page":"2207","article-title":"Organization and nucleotide sequence of the human KIT (mast\/stem cell growth factor receptor) proto-oncogene","volume":"7","author":"Giebel","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.iac.2014.01.009_bib17","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/335088a0","article-title":"The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus","volume":"335","author":"Chabot","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.iac.2014.01.009_bib18","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbrc.2005.09.150","article-title":"Structure and regulation of Kit protein-tyrosine kinase\u2013the stem cell factor receptor","volume":"338","author":"Roskoski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.iac.2014.01.009_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.08.055","article-title":"Signaling by Kit protein-tyrosine kinase\u2013the stem cell factor receptor","volume":"337","author":"Roskoski","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.iac.2014.01.009_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0092-8674(02)00741-9","article-title":"The conformational plasticity of protein kinases","volume":"109","author":"Huse","year":"2002","journal-title":"Cell"},{"key":"10.1016\/j.iac.2014.01.009_bib21","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1128\/MCB.23.9.3067-3078.2003","article-title":"Autoinhibition of the kit receptor tyrosine kinase by the cytosolic juxtamembrane region","volume":"23","author":"Chan","year":"2003","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.iac.2014.01.009_bib22","doi-asserted-by":"crossref","first-page":"e1002068","DOI":"10.1371\/journal.pcbi.1002068","article-title":"Mutation D816V alters the internal structure and dynamics of c-KIT receptor cytoplasmic region: implications for dimerization and activation mechanisms","volume":"7","author":"Laine","year":"2011","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.iac.2014.01.009_bib23","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.it.2008.07.004","article-title":"The multiple roles of phosphoinositide 3-kinase in mast cell biology","volume":"29","author":"Kim","year":"2008","journal-title":"Trends Immunol"},{"key":"10.1016\/j.iac.2014.01.009_bib24","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3389\/fonc.2013.00165","article-title":"The paradox of Akt-mTOR interactions","volume":"3","author":"Vadlakonda","year":"2013","journal-title":"Front Oncol"},{"key":"10.1016\/j.iac.2014.01.009_bib25","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/gene.2010.35","article-title":"Mast cell homeostasis and the JAK-STAT pathway","volume":"11","author":"Morales","year":"2010","journal-title":"Genes Immun"},{"key":"10.1016\/j.iac.2014.01.009_bib26","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1093\/emboj\/17.21.6250","article-title":"Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation","volume":"17","author":"Timokhina","year":"1998","journal-title":"EMBO J"},{"key":"10.1016\/j.iac.2014.01.009_bib27","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood.V98.2.343","article-title":"Lyn is required for normal stem cell factor-induced proliferation and chemotaxis of primary hematopoietic cells","volume":"98","author":"O'Laughlin-Bunner","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib28","doi-asserted-by":"crossref","first-page":"5546","DOI":"10.1038\/sj.onc.1202929","article-title":"Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor\/c-kit mediated activation of the Ras\/MAP kinase pathway and c-fos induction","volume":"18","author":"Lennartsson","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.iac.2014.01.009_bib29","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1182\/blood.V99.5.1866","article-title":"Requirement of Gab2 for mast cell development and KitL\/c-Kit signaling","volume":"99","author":"Nishida","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib30","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cellsig.2005.11.005","article-title":"Fyn kinase acts upstream of Shp2 and p38 mitogen-activated protein kinase to promote chemotaxis of mast cells towards stem cell factor","volume":"18","author":"Samayawardhena","year":"2006","journal-title":"Cell Signal"},{"key":"10.1016\/j.iac.2014.01.009_bib31","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00018-003-2349-8","article-title":"Mast cells stimulated by membrane-bound, but not soluble, steel factor are dependent on phospholipase C activation","volume":"60","author":"Trieselmann","year":"2003","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.iac.2014.01.009_bib32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/modpathol.2012.199","article-title":"Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications","volume":"26","author":"Ryan","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.iac.2014.01.009_bib33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1177\/0009922808318344","article-title":"Cutaneous mastocytosis: a review focusing on the pediatric population","volume":"47","author":"Briley","year":"2008","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.iac.2014.01.009_bib34","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.hoc.2012.08.001","article-title":"Systemic mastocytosis: disease overview, pathogenesis, and treatment","volume":"26","author":"Pardanani","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.iac.2014.01.009_bib35","first-page":"174","article-title":"Guidelines and diagnostic algorithm for patients with suspected systemic mastocytosis: a proposal of the Austrian competence network (AUCNM)","volume":"3","author":"Valent","year":"2013","journal-title":"Am J Blood Res"},{"key":"10.1016\/j.iac.2014.01.009_bib36","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.jaci.2013.05.026","article-title":"Gastrointestinal manifestations in\u00a0mastocytosis: a study of 83 patients","volume":"132","author":"Sokol","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.01.009_bib37","doi-asserted-by":"crossref","first-page":"832","DOI":"10.5858\/arpa.2011-0325-RS","article-title":"Systemic mastocytosis with associated clonal hematologic nonmast cell lineage disease: a clinicopathologic review","volume":"136","author":"Stoecker","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.iac.2014.01.009_bib38","series-title":"World Health Organization (WHO) classification of tumours. Pathology & genetics. Tumours of haematopoietic and lymphoid tissues","first-page":"291","article-title":"Mastocytosis (mast cell disease)","author":"Valent","year":"2001"},{"key":"10.1016\/j.iac.2014.01.009_bib39","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.iac.2014.01.009_bib40","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2014.01.009_bib41","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/10428190400010775","article-title":"Mastocytosis: pathology, genetics, and current options for therapy","volume":"46","author":"Valent","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.iac.2014.01.009_bib42","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1182\/blood-2010-06-289959","article-title":"KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib","volume":"118","author":"Gleixner","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib43","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2014.01.009_bib44","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0145-2126(01)00019-4","article-title":"A\u00a0case of \u2018smouldering\u2019 mastocytosis with high mast cell burden, monoclonal myeloid cells, and C-KIT mutation Asp-816-Val","volume":"25","author":"Jordan","year":"2001","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2014.01.009_bib45","first-page":"159","article-title":"Mastocytosis: a paradigmatic example of a rare disease with complex biology and pathology","volume":"3","author":"Valent","year":"2013","journal-title":"Am J Cancer Res"},{"key":"10.1016\/j.iac.2014.01.009_bib46","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product","volume":"92","author":"Furitsu","year":"1993","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.iac.2014.01.009_bib47","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/blood.V83.9.2619.2619","article-title":"Ligand-independent activation of c-kit receptor tyrosine kinase in a murine mastocytoma cell line P-815 generated by a point mutation","volume":"83","author":"Tsujimura","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib48","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.1016\/j.iac.2014.01.009_bib49","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.iac.2014.01.009_bib50","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1084\/jem.20050807","article-title":"Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation","volume":"202","author":"Zappulla","year":"2005","journal-title":"J\u00a0Exp Med"},{"key":"10.1016\/j.iac.2014.01.009_bib51","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"Buttner","year":"1998","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2014.01.009_bib52","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1525-1578(10)60552-1","article-title":"c-kit Mutations in patients with childhood-onset mastocytosis and genotype-phenotype correlation","volume":"7","author":"Yanagihori","year":"2005","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.iac.2014.01.009_bib53","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000096907","article-title":"C-kit Asp-816-Val mutation analysis in patients with mastocytosis","volume":"214","author":"Verzijl","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.iac.2014.01.009_bib54","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations","volume":"130","author":"Bodemer","year":"2010","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.iac.2014.01.009_bib55","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jmoldx.2010.10.004","article-title":"Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay","volume":"13","author":"Kristensen","year":"2011","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.iac.2014.01.009_bib57","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1600-0609.2012.01789.x","article-title":"Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis","volume":"89","author":"Kristensen","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.iac.2014.01.009_bib58","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes","volume":"125","author":"Teodosio","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.iac.2014.01.009_bib59","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1182\/blood-2012-09-458521","article-title":"International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis","volume":"121","author":"Gotlib","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib60","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2014.01.009_bib61","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1182\/blood-2012-07-442400","article-title":"Mast cell leukemia","volume":"121","author":"Georgin-Lavialle","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib62","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A\u00a0new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.iac.2014.01.009_bib63","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/labinvest.3700524","article-title":"Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation","volume":"87","author":"Nakagomi","year":"2007","journal-title":"Lab Invest"},{"key":"10.1016\/j.iac.2014.01.009_bib64","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1586\/ehm.12.12","article-title":"Diagnosis, progression patterns and prognostication in mastocytosis","volume":"5","author":"Sperr","year":"2012","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.iac.2014.01.009_bib65","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.leukres.2011.05.006","article-title":"Tyrosine kinase inhibitors in the treatment of systemic mastocytosis","volume":"35","author":"Ustun","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2014.01.009_bib66","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib67","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S0145-2126(02)00041-3","article-title":"Detection of c-kit point mutation Asp-816 --> Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia","volume":"26","author":"Sotlar","year":"2002","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2014.01.009_bib68","doi-asserted-by":"crossref","first-page":"3769","DOI":"10.1182\/blood-2009-05-220145","article-title":"Prognostically relevant breakdown of 123\u00a0patients with systemic mastocytosis associated with other myeloid malignancies","volume":"114","author":"Pardanani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib69","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1002\/path.2677","article-title":"Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD)","volume":"220","author":"Sotlar","year":"2010","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.iac.2014.01.009_bib70","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1200\/JCO.2012.41.9549","article-title":"Mast cell sarcoma: a rare and aggressive entity\u2013report of two cases and review of the literature","volume":"31","author":"Georgin-Lavialle","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.iac.2014.01.009_bib71","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A\u00a0novel K509I mutation of KIT identified in familial mastocytosis\u2013in\u00a0vitro and in\u00a0vivo responsiveness to imatinib therapy","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"10.1016\/j.iac.2014.01.009_bib72","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.exphem.2011.05.009","article-title":"Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis","volume":"39","author":"Wasag","year":"2011","journal-title":"Exp Hematol"},{"key":"10.1016\/j.iac.2014.01.009_bib73","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood-2008-03-147785","article-title":"Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation","volume":"112","author":"Hoffmann","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib74","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1182\/blood-2009-06-226027","article-title":"Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations","volume":"116","author":"Yang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib75","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.bbrc.2011.05.111","article-title":"Mechanism of activation of human c-KIT kinase by internal tandem duplications of the juxtamembrane domain and point mutations at aspartic acid 816","volume":"410","author":"Kim","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.iac.2014.01.009_bib76","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clml.2012.08.004","article-title":"Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications","volume":"13","author":"Bougherara","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.iac.2014.01.009_bib77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1128\/MCB.01153-06","article-title":"Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling","volume":"27","author":"Xiang","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.iac.2014.01.009_bib78","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.molcel.2009.09.019","article-title":"Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes","volume":"36","author":"Choudhary","year":"2009","journal-title":"Mol Cell"},{"key":"10.1016\/j.iac.2014.01.009_bib79","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1182\/blood.V98.4.1195","article-title":"The Kit-activating mutation D816V enhances stem cell factor\u2013dependent chemotaxis","volume":"98","author":"Taylor","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib80","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1182\/blood.V98.5.1365","article-title":"Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant","volume":"98","author":"Chian","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib81","doi-asserted-by":"crossref","first-page":"11039","DOI":"10.1074\/jbc.M808058200","article-title":"The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction","volume":"284","author":"Sun","year":"2009","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.iac.2014.01.009_bib82","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/blood-2007-02-076471","article-title":"The tyrosine kinase FES is an essential effector of KITD816V proliferation signal","volume":"110","author":"Voisset","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib83","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1182\/blood-2011-06-359984","article-title":"mTORC1 and mTORC2 differentially regulate homeostasis of neoplastic and non-neoplastic human mast cells","volume":"118","author":"Smrz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib84","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1182\/blood-2007-09-115477","article-title":"Oncogenic Kit controls neoplastic mast cell growth through a Stat5\/PI3-kinase signaling cascade","volume":"112","author":"Harir","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib85","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","article-title":"Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells","volume":"108","author":"Gabillot-Carre","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib86","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.2353\/ajpath.2009.080953","article-title":"Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V","volume":"175","author":"Baumgartner","year":"2009","journal-title":"Am J Pathol"},{"key":"10.1016\/j.iac.2014.01.009_bib87","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.iac.2006.05.003","article-title":"KIT mutations in mastocytosis and their potential as therapeutic targets","volume":"26","author":"Gotlib","year":"2006","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.1016\/j.iac.2014.01.009_bib88","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/978-3-642-01222-8_7","article-title":"Dasatinib","volume":"184","author":"Lindauer","year":"2010","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.iac.2014.01.009_bib89","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis","volume":"38","author":"Aichberger","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.iac.2014.01.009_bib90","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1039\/b923848b","article-title":"Protein kinase inhibition of clinically important staurosporine analogues","volume":"27","author":"Gani","year":"2010","journal-title":"Nat Prod Rep"},{"issue":"9","key":"10.1016\/j.iac.2014.01.009_bib91","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3324\/haematol.2012.079202","article-title":"Synergistic growth-inhibitory effects of ponatinib and midostaurin (PKC412) on neoplastic mast cells carrying KIT D816V","volume":"98","author":"Gleixner","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.iac.2014.01.009_bib92","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.iac.2014.01.009_bib93","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1517\/13543784.2013.740010","article-title":"Therapeutic targeting of c-KIT in cancer","volume":"22","author":"Ashman","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.iac.2014.01.009_bib94","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A\u00a0novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib95","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","article-title":"A\u00a0case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib","volume":"86","author":"Mital","year":"2011","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.iac.2014.01.009_bib96","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1200\/JCO.2011.38.9973","article-title":"Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis","volume":"30","author":"Alvarez-Twose","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.iac.2014.01.009_bib97","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.iac.2014.01.009_bib98","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1242\/dev.070771","article-title":"Tet family proteins and 5-hydroxymethylcytosine in development and disease","volume":"139","author":"Tan","year":"2012","journal-title":"Development"},{"key":"10.1016\/j.iac.2014.01.009_bib99","article-title":"Ten-eleven translocation-2 (TET2) gene in hematopoiesis and hematopoietic diseases","author":"Solary","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2014.01.009_bib100","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood-2010-12-325241","article-title":"Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies","volume":"118","author":"Li","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ccr.2011.06.025","article-title":"The role of TET2 in hematologic neoplasms","volume":"20","author":"Holmfeldt","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.iac.2014.01.009_bib102","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nature09586","article-title":"Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2","volume":"468","author":"Ko","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.iac.2014.01.009_bib103","doi-asserted-by":"crossref","first-page":"e85362","DOI":"10.1371\/journal.pone.0085362","article-title":"ASXL1 but not TET2 mutations adversely impact overall survival of patients suffering systemic mastocytosis with associated clonal hematologic non-mast-cell diseases","volume":"1","author":"Damaj","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.iac.2014.01.009_bib104","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/leu.2012.130","article-title":"Emerging roles of the spliceosomal machinery in myelodysplastic syndromes and other hematological disorders","volume":"26","author":"Visconte","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.iac.2014.01.009_bib105","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2013.095133","article-title":"SRSF2-P95 hotspot mutation is highly associated with advanced forms of mastocytosis and mutations in epigenetic regulator genes","author":"Hanssens","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.iac.2014.01.009_bib106","doi-asserted-by":"crossref","first-page":"17588","DOI":"10.1074\/jbc.M512616200","article-title":"Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor","volume":"281","author":"Cho","year":"2006","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.iac.2014.01.009_bib107","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2013.281","article-title":"Functional and cancer genomics of ASXL family members","volume":"109","author":"Katoh","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.iac.2014.01.009_bib108","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2009-07-230698","article-title":"Loss-of-function additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia","volume":"115","author":"Fisher","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib109","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","article-title":"Molecular aspects of myeloproliferative neoplasms","volume":"91","author":"Delhommeau","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.iac.2014.01.009_bib110","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.hoc.2012.07.006","article-title":"Role of TET2 and ASXL1 mutations in the pathogenesis of myeloproliferative neoplasms","volume":"26","author":"Abdel-Wahab","year":"2012","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.iac.2014.01.009_bib111","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A\u00a0comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.iac.2014.01.009_bib112","first-page":"407","article-title":"Multistage mastocytoma model characterized by autocrine IL-3 production","volume":"32","author":"Moroni","year":"1989","journal-title":"Haematol Blood Transfus"},{"key":"10.1016\/j.iac.2014.01.009_bib113","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/blood-2004-08-3306","article-title":"Repressible transgenic model of NRAS oncogene-driven mast cell disease in the mouse","volume":"106","author":"Wiesner","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib114","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1182\/blood-2004-08-009498","article-title":"Oncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice","volume":"108","author":"Parikh","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.iac.2014.01.009_bib115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3324\/haematol.2010.031690","article-title":"Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis","volume":"96","author":"Wilson","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.iac.2014.01.009_bib116","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/ng.2696","article-title":"Somatic SETBP1 mutations in myeloid malignancies","volume":"45","author":"Makishima","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.iac.2014.01.009_bib117","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1038\/sj.onc.1207779","article-title":"Point mutations in the RUNX1\/AML1 gene: another actor in RUNX leukemia","volume":"23","author":"Osato","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.iac.2014.01.009_bib118","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000101?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856114000101?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T06:22:15Z","timestamp":1689142935000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856114000101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":118,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0889856114000101"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2014.01.009","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}